Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International ConsortiumJack F. Shern, Javed Khan, Erin R. Rudzinski et al.|Journal of Clinical Oncology|2021Cited by 221
Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1–associated atypical neurofibromasAlexander Pemov, Douglas R. Stewart, Nancy F. Hansen et al.|Neuro-Oncology|2019Cited by 118
Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibilityMitchell J. Machiela, Margaret A. Tucker, Thomas G. P. Grünewald et al.|Nature Communications|2018Cited by 71
XAF1 as a modifier of p53 function and cancer susceptibilityEmília M. Pinto, Michael R. Clay, Bonald C. Figueiredo et al.|Science Advances|2020Cited by 58
GWAS Explorer: an open-source tool to explore, visualize, and access GWAS summary statistics in the PLCO AtlasMitchell J. Machiela, Neal D. Freedman, Wen‐Yi Huang et al.|Scientific Data|2023Cited by 25